ALDH7A1 and benign prostatic hyperplasia: Tadalafil was the first phosphodiesterase (PDE) 5 inhibitor with FDA approval for benign prostatic hyperplasia, and selective PDE inhibitors have shown an anti-inflammation effect and promise during treatments of psoriasis and psoriatic arthritis (38).